Vicon Industries VII 深 沪
等待开盘 12-16 09:30:00 美东时间
10.96
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 10.96
- 总市值 9951.24万
- 52周最高 8285.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 4500.00
- 委 比 0.00%
- 总股本 907.96万
- 历史最高 8285.00
- 量 比 0
- 振 幅 0.00%
- 历史最低 85.50
- 每 手 1
- 风险率 11.41%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cemtrex, Inc. Announces $2 Million Registered Direct Offering
Cemtrex, Inc. (NASDAQ: CETX) has agreed to sell approximately 666,667 shares to an institutional investor at $3 per share, raising $2 million. The transaction is expected to close on Dec 11, 2025, with proceeds用于 general corporate purposes and potential acquisitions. The offering is pursuant to an effective shelf registration on Form S-3 (No. 333-283995), with a prospectus supplement and accompanying prospectus available on the SEC’s website. Int...
12-11 14:15
Cemtrex Highlights Profitability Focus, Strategic Transformation, and Progress Toward Portfolio Expansion
Cemtrex, Inc. is advancing its multi-year transformation strategy, focusing on expanding operating income, improving margins, and scalability. The company is nearing the completion of its acquisition of a Texas-based aerospace and defense firm, Invocon, which is expected to boost profitability from fiscal 2026. Cemtrex has also signed a letter of intent to acquire a Tennessee-based industrial services business to enhance its AIS segment's geograp...
12-11 13:00
Cemtrex Enters into Agreement to Acquire Invocon, Adding Proven Aerospace & Defense Engineering Capabilities
Cemtrex has agreed to acquire Invocon, a Texas-based aerospace and defense engineering firm, for $7.06 million in early 2026. The deal will establish Cemtrex's new Aerospace & Defense segment, leveraging Invocon's expertise in mission-critical systems, advanced sensing technologies, and flight hardware. Invocon's 40-year history includes contributions to shuttle missions, the International Space Station, and high-reliability defense programs. The...
11-20 14:15
友芝友生物Y225（艾美赛珠单抗类似药）制剂专利获授权，有望提前6年上市
专利喜讯 近日，武汉友芝友生物制药股份有限公司（以下简称“友芝友生物”）Y225项目（罗氏血友病A双抗药物舒友立乐的生物类似药）取得...
10-29 09:24
Dupixent Pushes Sanofi's Quarterly Sales Past $14.5 Billion Mark
Sanofi Q3 sales beat estimates on strong Dupixent and new drug demand; reaffirms 2025 outlook with double-digit EPS growth expected.
10-24 22:47
旗舰药物Dupixent销售额单季度首超40亿欧元 赛诺菲(SNY.US)三季度利润超预期
赛诺菲三季度营收124.3亿欧元，同比增长2.3%；按固定汇率计算，每股收益为2.91欧元，超过了分析师平均预估的2.65欧元。
10-24 14:55
市值160亿，中国电商SaaS ERP龙头登陆港交所
原标题：市值160亿，中国电商SaaS ERP龙头登陆港交所 来源：直通IPO 四次闯关，中国最 大电商SaaS ERP提供商终于登陆港股市场。 10月21日...
10-23 00:02
Aveanna Heathcare dips 8%, prices 10M share secondary offering
Atlanta-based Aveanna Healthcare (NASDAQ:AVAH) priced its previously announced secondary offering by certain selling stockholders affiliated with J.H. Whitney Equity Partners VII, LLC of 10M shares ...
10-22 13:45
